E-钙黏蛋白缺陷乳腺癌中ROS1抑制剂的合成致死作用
该临床前研究利用CRISPR/Cas9构建CDH1突变乳腺癌细胞,通过扰动筛选发现E-钙黏蛋白缺陷与ROS1抑制存在合成致死效应。foretinib和crizotinib等临床ROS1抑制剂在多种E-钙黏蛋白缺陷乳腺癌模型中产生显著抗肿瘤作用,为分子分层II期临床试验提供依据。
要点
- E-钙黏蛋白缺陷乳腺癌对ROS1抑制剂敏感。
- foretinib和crizotinib可诱导缺陷细胞有丝分裂异常和多核化。
- 支持将已上市ROS1抑制剂用于分子分层临床试验。
核心结论
- E-钙黏蛋白缺陷与ROS1抑制在乳腺癌中呈合成致死,支持对已上市ROS1抑制剂开展分子分层II期临床试验。
研究设计与样本
- 在CRISPR/Cas9构建CDH1突变的乳腺癌细胞中进行扰动筛选,并在多种乳腺癌细胞系的大规模遗传筛选中验证。
- 在多种E-钙黏蛋白缺陷乳腺癌模型中进行体内抗肿瘤效果评估。
主要发现
- E-钙黏蛋白缺陷与ROS1抑制的合成致死效应在分子异质性背景下稳健,且可由foretinib和crizotinib等临床ROS1抑制剂触发。
- ROS1抑制剂在E-钙黏蛋白缺陷细胞中诱导有丝分裂异常和多核化,与胞质分裂缺陷及p120 catenin磷酸化和定位异常相关。
- ROS1抑制剂在多个E-钙黏蛋白缺陷乳腺癌模型中产生显著抗肿瘤效果。
临床怎么用
- 对E-钙黏蛋白缺陷的乳腺癌患者,可考虑评估已上市ROS1抑制剂(如crizotinib)的疗效。
局限性
- 证据来自临床前研究,尚未在患者中验证疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells with CRISPR/Cas9-engineered CDH1 mutations, we identified synthetic lethality between E-cadherin deficiency and inhibition of the tyrosine kinase ROS1. Data from large-scale genetic screens in molecularly diverse breast tumor cell lines established that the E-cadherin/ROS1 synthetic lethality was not only robust in the face of considerable molecular heterogeneity but was also elicited with clinical ROS1 inhibitors, including foretinib and crizotinib. ROS1 inhibitors induced mitotic abnormalities and multinucleation in E-cadherin-defective cells, phenotypes associated with a defect in cytokinesis and aberrant p120 catenin phosphorylation and localization. In vivo, ROS1 inhibitors produced profound antitumor effects in multiple models of E-cadherin-defective breast cancer. These data therefore provide the preclinical rationale for assessing ROS1 inhibitors, such as the licensed drug crizotinib, in appropriately stratified patients.Significance: E-cadherin defects are common in breast cancer but are currently not targeted with a precision medicine approach. Our preclinical data indicate that licensed ROS1 inhibitors, including crizotinib, should be repurposed to target E-cadherin-defective breast cancers, thus providing the rationale for the assessment of these agents in molecularly stratified phase II clinical trials. Cancer Discov; 8(4); 498-515. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 371.
引用
- Bajrami I, Marlow R, van de Ven M, et al. E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. Cancer Discov. 2018. PMID: 29610289. doi:10.1158/2159-8290.CD-17-0603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。